Evidence map›Paper›PMID 23419600›Full record

ArticleInternational journal of obesity (2005)2013

Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass.

C Dirksen, N B Jørgensen, K N Bojsen-Møller, U Kielgast, S H Jacobsen, T R Clausen, D Worm, B Hartmann, J F Rehfeld, M Damgaard and 4 more

Registry-linked trialAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in International journal of obesity (2005), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03341429 (BARI-OPTIMISE), which is not on this map. Cited by 100 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 5 pooled it
24.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03341429 phase4completedstarted 2018, after this paper: background citation

BARI-OPTIMISE: a Double-blinded, Randomised, Placebo-controlled Trial of Liraglutide 3.0 mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response Following Bariatric Surgery

Ran2018Enrolled70Registered outcomes18Posted comparisons0ConditionsObesityArmsLiraglutide Pen Injector [Saxenda], Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 5 syntheses or guidelines pooled it, 274 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Review
  14. Review
  15. Cholecystokinin: Clinical aspects of the new biology.Journal of internal medicine · 2025
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Observational

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

C Dirksen1] Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark [2] Novo Nordisk Foundation Centre for Basic Metabolic Research, the Panum Institute, University of Copenhagen, Copenhagen N, Denmark.
N B Jørgensen
K N Bojsen-Møller
U Kielgast
S H Jacobsen
T R Clausen
D Worm
B Hartmann
J F Rehfeld
M Damgaard
J L Madsen
S Madsbad
J J Holst
D L Hansen
University of Copenhagen · DKHvidovre Hospital · DKNovo Nordisk Foundation · DKNovo Nordisk (Denmark) · DKUniversity College Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo identify factors contributing to the variation in weight loss after Roux-en-Y gastric bypass (RYGB).

designCross-sectional study of patients with good (excess body mass index lost (EBL) >60%) and poor weight loss response (EBL <50%) >12 months after RYGB and a lean control group matched for age and gender. MATERIALS AND

methodsSixteen patients with good weight loss response, 17 patients with poor weight loss response, and eight control subjects were included in the study. Participants underwent dual energy X-ray absorptiometry scan, indirect calorimetry and a 9 h multiple-meal test with measurements of glucose, insulin, total bile acids (TBA), glucagon-like peptide (GLP)-1, peptide YY3-36 (PYY), cholecystokinin (CCK), ghrelin, neurotensin and pancreatic polypeptide (PP) as well as assessment of early dumping and appetite.

resultsSuppression of hunger was more pronounced in the good than the poor responders in response to the multiple-meal test (P=0.006). In addition, the good responders had a larger release of GLP-1 (P=0.009) and a greater suppression of ghrelin (P=0.037) during the test, whereas the postprandial secretion of CCK was highest in the poor responders (P=0.005). PYY, neurotensin, PP and TBA release did not differ between the RYGB-operated groups. Compared with control subjects, patients had exaggerated release of GLP-1 (P<0.001), PYY (P=0.008), CCK (P=0.010) and neurotensin (P<0.001). Early dumping was comparable in the good and poor responders, but more pronounced than in controlled subjects. Differences in resting energy expenditure between the three groups were entirely explained by differences in body composition.

conclusionFavorable meal-induced changes in hunger and gut hormone release in patients with good compared with poor weight loss response support the role of gut hormones in the weight loss after RYGB.

Indexed as

Appetite RegulationEnergy MetabolismGastric BypassWeight LossAbsorptiometry, PhotonBile Acids and SaltsBlood GlucoseBody Mass IndexCholecystokininCross-Sectional StudiesDumping SyndromeFemaleFollow-Up StudiesGhrelinGlucagon-Like Peptide 1HumansBile Acids and SaltsBlood GlucoseCholecystokininGhrelinGlucagon-Like Peptide 1NeurotensinPeptide YY

Identifiers

PMID23419600
OpenAlexW2049394141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.